Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the two alternate primary endpoints of
radiographic progression-free survival (rPFS) and overall survival (OS) in patients with
progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best
supportive/best standard of care versus patients treated with best supportive/best standard
of care alone.